Overview

Phase 1, Open-label, Drug-drug Interaction Study to Assess Effect Between Radiprodil and the Co-administered Drugs.

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-08-30

Target enrollment:

Participant gender:

Summary

This is a Phase 1, open-label, 3-period study to determine radiprodil's potential to act as a perpetrator of cytochrome P-450 (CYP) metabolic pathways and transporter pathways. The study will evaluate the pharmacokinetics (PK) and safety effects of co-administration of radiprodil with oral midazolam, rosuvastatin, warfarin, digoxin, and omeprazole in healthy adult subjects. The study will be conducted in 1 cohort of healthy adult participants only.

Phase:

PHASE1

Details

Lead Sponsor:

GRIN Therapeutics, Inc.

Collaborator:

Avance Clinical Pty Ltd.

Treatments:

radiprodil